Dysmenorrhea – Pipeline Insight, 2020

DelveInsight’s, “Dysmenorrhea – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dysmenorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Dysmenorrhea Understanding
Dysmenorrhea: Overview
Dysmenorrhea causes severe and frequent cramps and pain during your period. It may be either primary or secondary.
• Primary dysmenorrhea. This occurs when you first start your period and continues throughout your life. It is usually life-long. It can cause severe and frequent menstrual cramping from severe and abnormal uterine contractions.
• Secondary dysmenorrhea. This type is due to some physical cause. It usually starts later in life. It may be caused by another medical condition, such as pelvic inflammatory disease or endometriosis.
Symptoms
The following are the most common symptoms of dysmenorrhea. However, each person may experience symptoms differently. Symptoms may include:
• Cramping in the lower abdomen
• Pain in the lower abdomen
• Low back pain
• Pain radiating down the legs
• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Weakness
• Fainting
• Headaches
Diagnosis
To diagnose dysmenorrhea, the health care provider will evaluate your medical history and do a complete physical and pelvic exam. Other tests may include:
• Ultrasound. This test uses high-frequency sound waves to create an image of the internal organs.
• Magnetic resonance imaging (MRI). This test uses large magnets, radiofrequencies, and a computer to make detailed images of organs and structures within the body.
• Laparoscopy. This minor procedure uses a laparoscope. This is a thin tube with a lens and a light. It is inserted into an incision in the abdominal wall. Using the laparoscope to see into the pelvic and abdomen area, the doctor can often detect abnormal growths.
• Hysteroscopy. This is the visual exam of the canal of the cervix and the inside of the uterus. It uses a viewing instrument (hysteroscope) inserted through the vagina.
Treatment
Treatment to manage dysmenorrhea symptoms may include:
• Prostaglandin inhibitors, such as nonsteroidal anti-inflammatory medications, or NSAIDs, such as aspirin and ibuprofen (to reduce pain)
• Acetaminophen
• Oral contraceptives (ovulation inhibitors)
• Progesterone (hormone treatment)
• Diet changes (to increase protein and decrease sugar and caffeine intake)
• Vitamin supplements
• Regular exercise
• Heating pad across the abdomen
Dysmenorrhea Emerging Drugs Chapters
This segment of the Dysmenorrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dysmenorrhea Emerging Drugs
• Pelubiprofen - Daewon Pharmaceutical
Pelubiprofen is a cyclooxygenase 2 (COX-2) inhibitor approved for the treatment of osteoarthritis and back pain. It is currently in phase III stage of development for
• Pure Femme Tablets: Pure Green
Pure Femme Tablets is being developed by Pure Green for the treatment of Dysmenorrhea. It is currently in phase II stage of development.
• PNB 001: PNB Vesper Life Science
PNB 001 is being developed by PNB Vesper Life Science for the treatment of Dysmenorrhoea. PNB-001 is an isoform-selective antagonist that binds to CCK2 at 20 nM. In an isolated tissue assay, using CCK-5 as agonist the antagonizing properties were confirmed. L-365,260 was used as best CCK2 gastrin antagonist standard and PNB-001 was 10 times more potent and of much higher magnitude. It is currently in phase I stage of development.
Further product details are provided in the report……..
Dysmenorrhea: Therapeutic Assessment
This segment of the report provides insights about the different Dysmenorrhea drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Dysmenorrhea
There are approx. 10+ key companies which are developing the therapies for Dysmenorrhea. The companies which have their Dysmenorrhea drug candidates in the most advanced stage, i.e. phase III include Daewon Pharmaceutical and others
• Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Dysmenorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dysmenorrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dysmenorrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dysmenorrhea drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Dysmenorrhea R&D. The therapies under development are focused on novel approaches to treat/improve Dysmenorrhea.
• Intellectual property of PNB-001 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. USPTO has issued the patent on December 28, 2014.
Dysmenorrhea Report Insights
• Dysmenorrhea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Dysmenorrhea Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Dysmenorrhea drugs?
• How many Dysmenorrhea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dysmenorrhea?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dysmenorrhea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dysmenorrhea and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Daewon Pharmaceutical
• Pure Green
• PNB Vesper Life Science Nobelpharma
• Bayer
• Laboratorios Andromaco
• Juniper Pharmaceuticals
• Vantia
• PDC Biotech GmbH

Key Products
• NPC-16
• BAY86-5300
• Meloxicam
• Lidocaine
• VA111913
• PDC31
• Pelubiprofen
• Pure Femme Tablets
• PNB 001